These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Elucidation of D3 receptor function in vivo: do D3 receptors mediate inhibition of dopamine neuronal activity? Routledge C; Thorn L; Ashmeade T; Taylor S Biochem Soc Trans; 1996 Feb; 24(1):199-201. PubMed ID: 8674661 [No Abstract] [Full Text] [Related]
3. The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved? Maj J; Rogóz Z; Skuza G J Neural Transm (Vienna); 1999; 106(11-12):1063-73. PubMed ID: 10651103 [TBL] [Abstract][Full Text] [Related]
4. Effects of putative dopamine D3 receptor agonists, 7-OH-DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats. Kurashima M; Yamada K; Nagashima M; Shirakawa K; Furukawa T Pharmacol Biochem Behav; 1995 Nov; 52(3):503-8. PubMed ID: 8545466 [TBL] [Abstract][Full Text] [Related]
5. Effects of D3/D2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat. Caine SB; Geyer MA; Swerdlow NR Neuropsychopharmacology; 1995 Apr; 12(2):139-45. PubMed ID: 7779242 [TBL] [Abstract][Full Text] [Related]
6. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Gurevich EV; Bordelon Y; Shapiro RM; Arnold SE; Gur RE; Joyce JN Arch Gen Psychiatry; 1997 Mar; 54(3):225-32. PubMed ID: 9075463 [TBL] [Abstract][Full Text] [Related]
7. (S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist. TenBrink RE; Bergh CL; Duncan JN; Harris DW; Huff RM; Lahti RA; Lawson CF; Lutzke BS; Martin IJ; Rees SA; Schlachter SK; Sih JC; Smith MW J Med Chem; 1996 Jun; 39(13):2435-7. PubMed ID: 8691438 [No Abstract] [Full Text] [Related]
8. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Svensson K; Carlsson A; Huff RM; Kling-Petersen T; Waters N Eur J Pharmacol; 1994 Oct; 263(3):235-43. PubMed ID: 7843260 [TBL] [Abstract][Full Text] [Related]
9. Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol. Hashimoto T; Baba S; Ikeda H; Oda Y; Hashimoto K; Shimizu I Eur J Pharmacol; 2018 Jul; 830():26-32. PubMed ID: 29684390 [TBL] [Abstract][Full Text] [Related]
10. Quinpirole-induced 50 kHz ultrasonic vocalization in the rat: role of D2 and D3 dopamine receptors. Brudzynski SM; Komadoski M; St Pierre J Behav Brain Res; 2012 Jan; 226(2):511-8. PubMed ID: 22015714 [TBL] [Abstract][Full Text] [Related]
11. Antipsychotics with inverse agonist activity at the dopamine D3 receptor. Griffon N; Pilon C; Sautel F; Schwartz JC; Sokoloff P J Neural Transm (Vienna); 1996; 103(10):1163-75. PubMed ID: 9013403 [TBL] [Abstract][Full Text] [Related]
12. [Functional role of dopamine D3 receptor in schizophrenia]. Semba J Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325 [TBL] [Abstract][Full Text] [Related]
13. Recent advances in the development of dopamine D(3) receptor agonists and antagonists. Crider AM; Scheideler MA Mini Rev Med Chem; 2001 May; 1(1):89-99. PubMed ID: 12369994 [TBL] [Abstract][Full Text] [Related]
14. Lack of discrimination by agonists for D2 and D3 dopamine receptors. Burris KD; Pacheco MA; Filtz TM; Kung MP; Kung HF; Molinoff PB Neuropsychopharmacology; 1995 Jul; 12(4):335-45. PubMed ID: 7576010 [TBL] [Abstract][Full Text] [Related]